Get the Stockscreener App
313.24
1.05%
3.3102
Natera Inc stock is traded at $313.24, with a volume of 735.70K.
It is up +1.05% in the last 24 hours and up +15.39% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$309.93
Open:
$310.49
24h Volume:
735.70K
Relative Volume:
0.51
Market Cap:
$45.18B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-190.86
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-1.63%
1M Performance:
+15.39%
6M Performance:
+48.25%
1Y Performance:
+92.11%
1-Day Range:
$308.40
$318.61
1-Week Range:
$305.00
$321.72
52-Week Range:
$156.71
$326.03
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
313.42 | 44.67B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
586.05 | 217.52B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.15 | 142.32B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.83 | 43.41B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.65 | 41.95B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer - Yahoo Finance
Abbot Financial Management Inc. Takes Position in Natera, Inc. $NTRA - MarketBeat
Empowered Funds LLC Sells 9,708 Shares of Natera, Inc. $NTRA - MarketBeat
Natera director Jonathan Sheena sells $2.89m in stock By Investing.com - Investing.com Nigeria
Natera executive chairman Matthew Rabinowitz sells $641,800 stock By Investing.com - Investing.com Australia
Natera executive chairman Matthew Rabinowitz sells $641,800 stock - Investing.com
Net debt of Natera, Inc. – HAM:45E - TradingView
Natera director Jonathan Sheena sells $2.89m in stock - Investing.com
Natera (NTRA) Stock May Be 49% Undervalued As Guidance Rises - Yahoo Finance
Leeward Financial Partners LLC Invests $5.31 Million in Natera, Inc. $NTRA - MarketBeat
Natera (NTRA) Lands Kupando Trial Deal, Is The Upside Already Priced In? - simplywall.st
GSA Capital Partners LLP Invests $3.08 Million in Natera, Inc. $NTRA - MarketBeat
7,701 Shares in Natera, Inc. $NTRA Bought by Focus Partners Advisor Solutions LLC - MarketBeat
Natera (NTRA) Lands New Trial Collaboration But Is The Valuation Already Priced In - Yahoo Finance
Natera co-founder, Director Sheena Jonathan sells 6,000 shares worth $1.95 million - Bitget
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference - MarketBeat
5 Insightful Analyst Questions From Natera’s Q2 Earnings Call - Yahoo Finance
Natera director Jonathan Sheena sells $1.95m in common stock By Investing.com - Investing.com Australia
Natera director Jonathan Sheena sells $1.95m in common stock - Investing.com
T. Rowe Price Associates (NTRA) discloses 9.0M-share Natera stake in updated 13G - Stock Titan
Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales - simplywall.st
Natera (NASDAQ:NTRA) Stock Rating Upgraded by Zacks Research - MarketBeat
NTRA Maintained by Citigroup -- Price Target Raised to $365 - GuruFocus
Citigroup Raises Natera (NASDAQ:NTRA) Price Target to $365.00 - MarketBeat
NATERA, INC. : GUGGENHEIM RAISES TARGET PRICE TO $360 FROM $290 - webull.com
Natera at Canaccord Genuity conference: Signatera drives growth By Investing.com - Investing.com Nigeria
Natera at Canaccord Genuity conference: Signatera drives growth - Investing.com
NTRA Maintained by Piper Sandler -- Price Target Raised to $363. - GuruFocus
NTRA Maintained by Stephens & Co. -- Price Target Raised to $350 - GuruFocus
Natera (NASDAQ:NTRA) Price Target Raised to $363.50 at Piper Sandler - MarketBeat
Natera and Kupando Therapeutics Partner for Phase I Trial of KUP-101 in Advanced Skin Cancers - The Dermatology Digest
NTRA Maintained by Guggenheim -- Price Target Raised to $360 - GuruFocus
Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers - TradingView
Guggenheim Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $360 - Moomoo
Natera partners with Kupando for phase 1 cancer trial in Germany - Investing.com Australia
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers - Yahoo Finance
E. Ohman J or Asset Management AB Sells 24,163 Shares of Natera, Inc. $NTRA - MarketBeat
Technical Reactions to NTRA Trends in Macro Strategies - Stock Traders Daily
NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth - Yahoo Finance
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs - The Motley Fool
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests - The Motley Fool
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know - The Motley Fool
A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It - The Motley Fool
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know - The Motley Fool
Natera Preps for MRD Test Expansion, Entry Into Early Cancer Detection on Heels of Recent Catalysts - 360dx.com
Natera Insider Sold Shares Worth $2,888,325, According to a Recent SEC Filing - marketscreener.com
US$317That's What Analysts Think Natera, Inc. (NASDAQ:NTRA) Is Worth After These Results - Moomoo
Natera (NTRA) Is Up 20.3% After Raising 2026 Guidance And Expanding Signatera’s Oncology Reach - simplywall.st
Natera (NTRA) Is Up 20.3% After Shelf Filing And Higher 2026 Guidance Has The Bull Case Changed? - finance.yahoo.com
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday - Sahm
NATERA, INC. : BERNSTEIN RAISES TARGET PRICE TO $365 FROM $310 - webull.com
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
Aug 07 '26 |
Sale |
320.90 |
2,000 |
641,800 |
2,000 |
| Sheena Jonathan | CO-FOUNDER |
Aug 07 '26 |
Sale |
315.66 |
9,150 |
2,888,325 |
236,464 |
1.44%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):